TABLE 6.
IC-50 values of anti-protozoal agents effective against Blastocystis isolates using the resazurin assay
| Drug | IC50 [μg/ml (μM)] |
|||
|---|---|---|---|---|
| Subtype 7 (Mzr) isolates |
Subtype 4 (Mzs) isolates |
|||
| B | E | WR-1 | S | |
| NTZb | 0.62 ± 0.07 (2.01) | 1.14 ± 0.49 (3.7) | 4.15 ± 0.41 (13.48) | 8 ± 4.7 (26) |
| FURb | 0.65 ± 0.05 (2.88) | 1.06 ± 0.4 (4.7) | 0.49 ± 0.01 (2.17) | 0.475 ± 0.05 (2.1) |
| MQb | 1.49 ± 0.83 (3.93) | 1.85 ± 0.88 (4.88) | 4.7 ± 0.35 (12.4) | 5.1 ± 0.58 (13.46) |
| QCb | 2.8 ± 0.56 (7) | 1.9 ± 0.2 (4.75) | 5.1 ± 0.47 (12.75) | 4.9 ± 0.53 (12.25) |
| QNb | 5.1 ± 1.1 (15.7) | 4.3 ± 2.4 (13.24) | 3.2 ± 0.52 (9.8) | 5.4 ± 1.4 (16.63) |
| EMc | 1.03 ± 0.4 (2.13) | 1.32 ± 0.9 (2.73) | NSa | NS |
| TMP:SMZ 1:2b | 4.7 ± 0.5 | 5.3 ± 0.62 | 3.2 ± 0.8 | 4.3 ± 0.48 |
| TMP:SMZ 1:5b | 22 ± 3.2 | 18.5 ± 1.3 | 24.5 ± 2.4 | 19 ± 0.46 |
| IAd | 0.34 ± 0.05 (1.83) | 0.2 ± 0.03 (1.08) | 0.33 ± 0.06 (1.78) | 0.26 ± 0.02 (1.4) |
a
N/S, not susceptible to ≤100-μg/ml concentration of the drug.
b
FDA-approved antimicrobial agent.
c
Antiparasitic agent with adverse side effects; not currently used in clinical practice.
d
Carcinogenic cysteine protease inhibitor; not clinically useful.